Monitor upcoming FDA milestones for Telomir-1 as triggers for potential $4 million in additional funding; assess the dilutive impact of 34.4 million new shares on existing shareholders; watch for clinical trial initiation as a potential catalyst.
Price Chart
Executive Summary
Telomir Pharmaceuticals completed the acquisition of TELI Pharmaceuticals, issuing 34.4 million shares to consolidate global rights to Telomir-1 (Telomir-Zn). As part of the deal, Bayshore Trust contributed $1 million upfront and committed to up to $4 million in milestone-based funding tied to FDA IND acceptance and Phase 1/2 trial initiation. The transaction strengthens Telomir's control over its lead asset but results in significant shareholder dilution.
Key Financial Metrics
Key Facts
- Telomir acquired 100% of TELI Pharmaceuticals in exchange for 34,389,710 restricted shares of common stock
- Bayshore Trust contributed $1 million at closing and committed to up to $4 million in milestone-based funding ($2M per milestone)
- Funding milestones are tied to FDA acceptance of an IND application and initiation of a Phase 1/2 clinical study for Telomir-1
- The deal consolidates global rights to Telomir-1 under a single corporate structure, eliminating prior geographic fragmentation
- The shares were issued unregistered under Section 4(a)(2) and Rule 506
Financial Impact
34.4 million new shares issued (significant dilution), $1 million immediate cash infusion, and potential $4 million in future milestone funding
Risk Factors
- Significant shareholder dilution from issuance of 34.4 million new shares
- Future funding is contingent on achieving regulatory and clinical milestones, creating execution risk
- Integration risk in consolidating the TELI operations and intellectual property
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-018867 |
| Exhibit: ex10-1.htm | 0001493152-26-018867 |
| Document: 0001493152-26-018867-index-headers.html | 0001493152-26-018867 |
| Document: 0001493152-26-018867-index.html | 0001493152-26-018867 |
| Document: 0001493152-26-018867.txt | 0001493152-26-018867 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 8-K | $1.20 | awaiting T+20 | — | $1.05 (−12.50%) |
Sep 17, 2026 5w ago | 8-K | $1.12 $1.05 | ▼ −6.25% | ▼ −7.46% | $1.05 (−6.25%) |
Sep 17, 2026 5w ago | Press Release | $1.12 $1.05 | ▼ −6.25% | ▼ −7.71% | $1.05 (−6.25%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $1.10 | ▼ −5.98% | ▼ −8.25% | $1.05 (−10.26%) |
Aug 19, 2026 9w ago | DEFA14A | $1.17 $1.12 | ▼ −4.27% | ▼ −2.32% | $1.05 (−10.26%) |
Aug 10, 2026 11w ago | 8-K | $1.17 $1.19 | ▲ +1.71% | ▲ +2.62% | $1.05 (−10.26%) |
Jun 15, 2026 19w ago | 8-K | $1.29 $1.24 | ▼ −3.88% | ▼ −3.13% | $1.05 (−18.60%) |
Jun 8, 2026 20w ago | 8-K | $1.21 $1.24 | ▲ +2.48% | ▲ +1.03% | $1.05 (−13.22%) |
Apr 24, 2026 26w ago | 8-K | $1.40 $1.30 | ▼ −7.14% | ▼ −11.17% | $1.05 (−25.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers